Clinical Trials | December 11, 2025
Lilly drug cuts risk of disease progression or death by 80% in trial
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
The study met its primary endpoint and all 11 secondary efficacy endpoints
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Subscribe To Our Newsletter & Stay Updated
